383 related articles for article (PubMed ID: 33766002)
1. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
Zhu C; Zhu J; Qian L; Liu H; Shen Z; Wu D; Zhao W; Xiao W; Zhou Y
BMC Cancer; 2021 Mar; 21(1):322. PubMed ID: 33766002
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and prognostic impact of lymphadenectomy and lymph node metastasis in clinically early-stage ovarian clear cell carcinoma.
Mahdi H; Moslemi-Kebria M; Levinson KL; Gojayev A; Lockhart D; Ali-Fehmi R; Munkarah AR
Int J Gynecol Cancer; 2013 Sep; 23(7):1226-30. PubMed ID: 23736258
[TBL] [Abstract][Full Text] [Related]
3. Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute.
Zhao T; Shao Y; Liu Y; Wang X; Guan L; Lu Y
J Ovarian Res; 2018 Jun; 11(1):53. PubMed ID: 29941051
[TBL] [Abstract][Full Text] [Related]
4. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
Sahin H; Sari ME; Cuylan ZF; Haberal AN; Sirvan L; Coban G; Yalcin I; Güngör T; Celik H; Meydanli MM; Ayhan A
Arch Gynecol Obstet; 2018 Apr; 297(4):1005-1013. PubMed ID: 29383437
[TBL] [Abstract][Full Text] [Related]
5. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
[TBL] [Abstract][Full Text] [Related]
6. Over-expression of RALYL suppresses the progression of ovarian clear cell carcinoma through inhibiting MAPK and CDH1 signaling pathways.
Xia Y; Ye S; Yang Y; Liu Y; Tong G
Int J Med Sci; 2021; 18(3):785-791. PubMed ID: 33437214
[No Abstract] [Full Text] [Related]
7. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
8. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival.
Diaz ES; Walts AE; Karlan BY; Walsh CS
Gynecol Oncol; 2013 Dec; 131(3):541-5. PubMed ID: 24041880
[TBL] [Abstract][Full Text] [Related]
9. [The relationship of preoperativelymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer].
Yang HM; Lou G
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):676-680. PubMed ID: 28926896
[No Abstract] [Full Text] [Related]
10. Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.
Chen W; Shan B; Zhou S; Yang H; Ye S
BMC Cancer; 2022 Jan; 22(1):92. PubMed ID: 35062908
[TBL] [Abstract][Full Text] [Related]
11. Lymphadenectomy for early-stage mucinous ovarian carcinoma.
Heyward QD; Nasioudis D; Cory L; Haggerty AF; Ko EM; Latif N
Int J Gynecol Cancer; 2021 Jan; 31(1):104-109. PubMed ID: 33243777
[TBL] [Abstract][Full Text] [Related]
12. The impact of lymphadenectomy on the survival outcomes of ovarian clear cell carcinoma: A retrospective study of the SEER database and Chinese registry.
Liu Y; Zhao W; Huang C; Chu R; Li Z; Wang Y; Song L; Li L
Eur J Surg Oncol; 2024 Mar; 50(3):107975. PubMed ID: 38295548
[TBL] [Abstract][Full Text] [Related]
13. Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary.
Mueller JJ; Holzapfel M; Han CH; Santos K; Gunderson C; Moore K; Erickson B; Leath CA; Diaz E; Walsh C; Wethington SL; Dejbakhsh SZ; Barakat RR; Gardner GJ; Hyman DM; Soslow RA; Leitao MM
Int J Gynecol Cancer; 2016 Jan; 26(1):120-4. PubMed ID: 26509849
[TBL] [Abstract][Full Text] [Related]
14. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
Kucukgoz Gulec U; Paydas S; Guzel AB; Vardar MA; Khatib G; Gumurdulu D
Arch Gynecol Obstet; 2015 Oct; 292(4):923-9. PubMed ID: 25855053
[TBL] [Abstract][Full Text] [Related]
15. Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.
Matsuo K; Machida H; Mandelbaum RS; Grubbs BH; Roman LD; Sood AK; Gershenson DM
Gynecol Oncol; 2019 May; 153(2):230-237. PubMed ID: 30797590
[TBL] [Abstract][Full Text] [Related]
16. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
Matsuo K; Hasegawa K; Yoshino K; Murakami R; Hisamatsu T; Stone RL; Previs RA; Hansen JM; Ikeda Y; Miyara A; Hiramatsu K; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Roman LD; Gabra H; Fotopoulou C; Sood AK
Eur J Cancer; 2015 Sep; 51(14):1978-88. PubMed ID: 26238017
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic analysis of 88 patients with ovarian clear cell carcinoma].
Ma SK; Zhang HT; Wu LY; Liu LY
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):784-8. PubMed ID: 18396695
[TBL] [Abstract][Full Text] [Related]
18. Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion.
Matsuo K; Yoshino K; Hasegawa K; Murakami R; Ikeda Y; Adachi S; Hiramatsu K; Yokoyama T; Nishimura M; Sheridan TB; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Fotopoulou C; Roman LD; Sood AK
Gynecol Oncol; 2015 Feb; 136(2):198-204. PubMed ID: 25497604
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
Quan C; Chen X; Wen H; Wu X; Li J
BMC Cancer; 2024 May; 24(1):565. PubMed ID: 38711015
[TBL] [Abstract][Full Text] [Related]
20. Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Shu CA; Zhou Q; Jotwani AR; Iasonos A; Leitao MM; Konner JA; Aghajanian CA
Gynecol Oncol; 2015 Nov; 139(2):236-41. PubMed ID: 26404183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
